PIP and pneumonia: North American data from the 2010–2014 SMART programs find that 4, 10 and 46% of ESBL-producing E. coli were susceptible to ceftriaxone, cefepime and ceftazidime, respectively [28], whereas 96–98 and 69% of ESBL-producing E. coli isolates from urinary tract [29] and from patients with pneumonia [30] were found susceptible in vitro to Pip–Taz, respectively.